Public Policy Resources

Share

Payer Coverage Policies of Tumor Biomarker and Pharmacogenomic Testing

March 24, 2023

Biomarker testing is key to unlocking precision medicine and improving cancer outcomes, however not all individuals are benefiting. In a survey of over 300 oncology providers, 66% reported that insurance coverage for biomarker testing is a moderate or significant barrier to appropriate testing for their patients. Additionally, 91% indicated that they consult clinical practice guidelines in their decision to recommend or order biomarker testing. Coverage for guideline-recommended biomarker tests is not universal and can be a barrier to cancer patients accessing treatments that can lead to improved survival and quality of life.    

PDF icon Download Payer Coverage Policies of Tumor Biomarker and Pharmacogenomic Testing Report

Related Resources

Survivor Views: One in Ten Impacted by Recent Drug Shortages

October 19, 2023

The nation’s drug shortage crisis continues to affect cancer patients and survivors with 1 in every 10 (10%) reporting impacts to care, a majority of whom have had difficulties finding substitute medications (68%) and cited treatment delays (45%).

Read more

Cancer Patients and Survivors Overwhelmingly Agree Biomarker Testing Improved Their Treatment

October 19, 2023

Our latest Survivor Views survey sees increases in biomarker testing since the question was last asked three years ago along with reduced cost and coverage barriers in that time. Cancer patients and survivors describe the benefits and overwhelmingly agree biomarker testing gave their providers information that improved their treatment. 

Read more